Biocryst Pharmaceuticals (BCRX) EBIT: 2010-2015
Historic EBIT for Biocryst Pharmaceuticals (BCRX) over the last 4 years, with Sep 2015 value amounting to -$13.2 million.
- Biocryst Pharmaceuticals' EBIT fell 13.37% to -$13.2 million in Q3 2015 from the same period last year, while for Sep 2015 it was -$37.4 million, marking a year-over-year decrease of 1.24%. This contributed to the annual value of -$45.8 million for FY2014, which is 49.01% down from last year.
- Latest data reveals that Biocryst Pharmaceuticals reported EBIT of -$13.2 million as of Q3 2015, which was down 346.39% from $5.3 million recorded in Q2 2015.
- Over the past 5 years, Biocryst Pharmaceuticals' EBIT peaked at $5.3 million during Q2 2015, and registered a low of -$15.2 million during Q4 2014.
- Moreover, its 3-year median value for EBIT was -$11.6 million (2014), whereas its average is -$9.0 million.
- Per our database at Business Quant, Biocryst Pharmaceuticals' EBIT tumbled by 139.28% in 2014 and then surged by 145.98% in 2015.
- Over the past 5 years, Biocryst Pharmaceuticals' EBIT (Quarterly) stood at -$11.0 million in 2011, then climbed by 11.51% to -$10.2 million in 2012, then decreased by 19.32% to -$6.3 million in 2013, then slumped by 139.28% to -$15.2 million in 2014, then declined by 13.37% to -$13.2 million in 2015.
- Its EBIT was -$13.2 million in Q3 2015, compared to $5.3 million in Q2 2015 and -$14.4 million in Q1 2015.